Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Real-time Estimate Cboe BZX  -  03:47 2022-09-29 pm EDT
39.66 USD   -1.43%
09/19Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
BU
09/12Transcript : Sage Therapeutics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 03:40 PM
CI
09/05Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating

08/03/2022 | 08:46am EDT


© MT Newswires 2022
All news about SAGE THERAPEUTICS, INC.
09/19Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating ..
BU
09/12Transcript : Sage Therapeutics, Inc. Presents at Morgan Stanley 20th Annual G..
CI
09/05Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
AQ
09/02Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..
MT
08/02Transcript : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02Sage Therapeutics Widens Q2 Net Loss as Revenue Declines
MT
08/02SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 6,93 M - -
Net income 2022 -519 M - -
Net cash 2022 1 121 M - -
P/E ratio 2022 -4,63x
Yield 2022 -
Capitalization 2 391 M 2 391 M -
EV / Sales 2022 183x
EV / Sales 2023 12,4x
Nbr of Employees 471
Free-Float 87,5%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 40,23 $
Average target price 57,81 $
Spread / Average Target 43,7%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-5.43%2 391
GILEAD SCIENCES, INC.-11.95%80 128
REGENERON PHARMACEUTICALS, INC.11.70%75 415
VERTEX PHARMACEUTICALS33.16%74 991
BIONTECH SE-48.10%32 514
WUXI APPTEC CO., LTD.-40.29%28 423